Dupilumab (brand name Dupixent) and tralokinumab (brand name Adbry) are injectable medications used to treat moderate-to-severe eczema (atopic dermatitis). These are biologic drugs that target specific parts of the immune system to reduce inflammation and the associated itching and rash.
Dupilumab (Dupixent) Injection for Eczema
- Mechanism of Action: Dupilumab is a biologic injection that works by blocking specific signaling molecules involved in inflammation. This helps to reduce the symptoms of eczema, such as itching, redness, and rash. It is approved for adults and children 6 months and older with moderate-to-severe eczema.
- Administration: Dupixent is administered via subcutaneous injection (under the skin).
- Additional Uses: Besides eczema, Dupixent also treats eosinophilic esophagitis and can help prevent asthma symptoms.
Tralokinumab (Adbry) Injection for Eczema
- Mechanism of Action: Similar to Dupilumab, Adbry targets specific immune system pathways implicated in eczema, alleviating inflammation and symptoms.
- Administration: Adbry is also given as a subcutaneous injection.
- Patient Population: Adbry is approved for individuals 12 years and older with moderate-to-severe atopic dermatitis.
Other Treatment Options
While injections like Dupilumab and Adbry are effective for moderate-to-severe eczema, other treatments exist. These include topical creams and ointments, light therapy, and oral medications. Hydrocortisone injections are used for conditions like tennis elbow, not eczema.
Note: This information is for general knowledge and does not constitute medical advice. Always consult with a dermatologist or healthcare professional for diagnosis and treatment of eczema. They can determine the best treatment plan based on your individual needs and medical history.
